These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
26. Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Relation to extrapyramidal side effects. Farde L; Nordström AL; Wiesel FA; Pauli S; Halldin C; Sedvall G Arch Gen Psychiatry; 1992 Jul; 49(7):538-44. PubMed ID: 1352677 [TBL] [Abstract][Full Text] [Related]
29. Typical antipsychotic drugs -- D(2) receptor occupancy and depressive symptoms in schizophrenia. Bressan RA; Costa DC; Jones HM; Ell PJ; Pilowsky LS Schizophr Res; 2002 Jul; 56(1-2):31-6. PubMed ID: 12084417 [TBL] [Abstract][Full Text] [Related]
30. Plasma homovanillic acid, plasma anti-D1 and -D2 dopamine-receptor activity, and negative symptoms in chronically mediated schizophrenia. Suzuki E; Kanba S; Nibuya M; Koshikawa H; Nakaki T; Yagi G Biol Psychiatry; 1992 Feb; 31(4):357-64. PubMed ID: 1348430 [TBL] [Abstract][Full Text] [Related]
31. Dopamine D2 and D3 receptor occupancy in normal humans treated with the antipsychotic drug aripiprazole (OPC 14597): a study using positron emission tomography and [11C]raclopride. Yokoi F; Gründer G; Biziere K; Stephane M; Dogan AS; Dannals RF; Ravert H; Suri A; Bramer S; Wong DF Neuropsychopharmacology; 2002 Aug; 27(2):248-59. PubMed ID: 12093598 [TBL] [Abstract][Full Text] [Related]
32. D1- and D2-dopamine receptor occupancy during treatment with conventional and atypical neuroleptics. Farde L; Wiesel FA; Nordström AL; Sedvall G Psychopharmacology (Berl); 1989; 99 Suppl():S28-31. PubMed ID: 2573104 [TBL] [Abstract][Full Text] [Related]
33. D2 dopamine receptor up-regulation, treatment response, neurological soft signs, and extrapyramidal side effects in schizophrenia: a follow-up study with 123I-iodobenzamide single photon emission computed tomography in the drug-naive state and after neuroleptic treatment. Schröder J; Silvestri S; Bubeck B; Karr M; Demisch S; Scherrer S; Geider FJ; Sauer H Biol Psychiatry; 1998 May; 43(9):660-5. PubMed ID: 9582999 [TBL] [Abstract][Full Text] [Related]
34. 5-HT2 and D2 receptor occupancy of olanzapine in schizophrenia: a PET investigation. Kapur S; Zipursky RB; Remington G; Jones C; DaSilva J; Wilson AA; Houle S Am J Psychiatry; 1998 Jul; 155(7):921-8. PubMed ID: 9659858 [TBL] [Abstract][Full Text] [Related]
35. Delayed normalization of central D2 dopamine receptor availability after discontinuation of haloperidol decanoate. Preliminary findings. Nyberg S; Farde L; Halldin C Arch Gen Psychiatry; 1997 Oct; 54(10):953-8. PubMed ID: 9337776 [TBL] [Abstract][Full Text] [Related]
36. D2-dopamine receptor occupancy differs between patients with and without extrapyramidal side effects. Scherer J; Tatsch K; Schwarz J; Oertel WH; Konjarczyk M; Albus M Acta Psychiatr Scand; 1994 Oct; 90(4):266-8. PubMed ID: 7831996 [TBL] [Abstract][Full Text] [Related]
37. An open clinical and biochemical study of ritanserin in acute patients with schizophrenia. Wiesel FA; Nordström AL; Farde L; Eriksson B Psychopharmacology (Berl); 1994 Feb; 114(1):31-8. PubMed ID: 7846205 [TBL] [Abstract][Full Text] [Related]